Skip to main content
. Author manuscript; available in PMC: 2013 Sep 20.
Published in final edited form as: Stroke. 2011 Jul 21;42(9):2672–2713. doi: 10.1161/STR.0b013e3182299496

Table 7.

Meta-Analyses of Randomized Trials of Blood Pressure–Lowering Treatment on Prevention of Dementia

Author Year of Publication Studies Sample Size (No. of Events/No. of Patients) Type of Effect P for Heterogeneity Main Results
Birns et al454 2006 PROGRESS SCOPE SHEP Syst-Eur 642/18 196 Fixed 0.18 0.89 (95% CI 0.75–1.04); P=0.15
Feigin et al453 2005 PROGRESS SCOPE SHEP Syst-Eur 883/23 505 Random 0.06 0.80 (95% CI 0.63–1.02); P=0.07
Peters et al444 2008 HYVET PROGRESS SHEP Syst-Eur 786/16 595 Random 0.49 0·87 (95% CI 0.76–1.00);P=0.045
McGuinness et al456 2008 SCOPE SHEP Syst-Eur 232/15 295 Fixed 0.16 0.89 (95% CI 0.69–1.16); P=0.38
McGuinness et al455 2009 HYVET SCOPE SHEP Syst-Eur 495/15 427 Fixed 0.30 0.89 (95% CI 0.74–1.07); P=0.21

PROGRESS indicates Perindopril Protection Against Recurrent Stroke Study; SCOPE, Study on Cognition and Prognosis in the Elderly; SHEP, Systolic Hypertension in the Elderly Program; Syst-Eur, Systolic Hypertension in Europe; CI, confidence interval; and HYVET, Hypertension in the Very Elderly Trial.